GeneThera Finalizes License and Research Agreement With Two Leading Italian Universities; Agreement Represents Key Step in Effort to Commercialize Diagnostic and Therapeutic Solutions for Johne's Disease
On Tuesday September 22, 2009, 8:00 am EDT
ARVADA, CO--(Marketwire - 09/22/09) - GeneThera, Inc. (Pinksheets:GTHR - News), an international biotechnology company, today announced it has finalized a license and research agreement with two Italian universities: Universita di Roma "Tor Vergata" (UNIROMA2) and Universita Cattolica del Sacro Cuore (UCSC).

The agreement will enable GeneThera to commence therapeutic testing of a breakthrough new compound developed by the universities. The compound, called LIPOSTIM, will be tested as a possible therapy against veterinary mycobacterial disorders such as Johne's disease, an infectious, fatal and as yet incurable bacterial ailment that affects the intestinal tract in livestock and may be linked to Irritable Bowel Syndrome (IBS) and Crohn's disease in humans.

Dr. Tony Milici, founder and CEO of GeneThera, said, "LIPOSTIM is at the heart of a potentially breakthrough treatment for Johne's disease, which has become a costly and expanding problem for the global agriculture, livestock and dairy industries. LIPOSTIM acts like a 'smart bomb,' and is able to significantly enhance antimycobacterial innate immune response while simultaneously limiting tissue damage. We believe this compound will provide us with a distinct competitive advantage, as to our knowledge no comparable type of therapy exists or is being tested."

Maurizio Fraziano, a professor of immunology at UNIROMA2, and Marco De Spirito, a professor of Physics at UCSC, jointly stated, "Our universities have been collaborating for more than a decade on the development of the LIPOSTIM compound, and we are excited that GeneThera will soon commence the field testing of this potentially breakthrough therapy. We look forward to working closely with the company on these critical next steps."

Milici said the license agreement represents an important advancement in GeneThera's broader efforts to commercialize both a diagnostic and therapeutic solution to Johne's and related diseases. As previously announced, GeneThera also is working in collaboration with the Universidad Nacional Autonoma de Mexico (UNAM) on a diagnostic test for Johne's disease. UNAM will support this effort in part by providing access to livestock at a forthcoming testing facility in Monterrey, Mexico. GeneThera also has reached an agreement with Roche Diagnostics, which will provide specialized equipment for the testing.

"Our next step will be the setup of our testing lab and related infrastructure in Monterrey, and I will personally oversee these efforts," Milici said. "The LIPOSTIM clinical trial is scheduled to begin soon thereafter."

Milici added that GeneThera is working to secure additional capital required to advance its current programs, and has been in discussions with the funding arm of the New Jersey-based Pharma Finance Conference, which was recently attended by GeneThera.

Leonardo Zangani, president of New Jersey based Zangani Investment Community and organizer of Pharma Finance Conference series, stated, "As it happens in every edition of Pharma Finance, we can see positive results both at the scientific and financial levels. The agreement between GeneThera, UNIROMA2 and UCSC is an example of this success."

About GeneThera, Inc.
Please read PR or go to website as kept exceeding 4000 characters! http://www.genethera.net.

Safe Harbor Statement
PLEASE READ PR, as I did not have enough space!

Contact:Dr. Milici at company #
HighPrincipalPfeiffer High Investor Relations, Inc.303-393-7044

Sorry about no link, but it is easily found on Yahoo Finance and listed as the most recent PR for this company!